Medically reviewed by William Truswell, MD Dandruff is a mild form of seborrheic dermatitis caused by an overgrowth of the yeast (fungus) Malassezia. It causes oiliness, dryness, white or yellow ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.

Potent topical steroids outperform mild ones in treating moderate atopic dermatitis in children, improving symptom control and quality of life.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Winters bring warm drinks and cosy layers, however, for those battling eczema, the winter season may not be pleasant. The ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

Probiotics may help with many health conditions. Although they're generally safe, it's important to talk with your doctor ...

Apogee Therapeutics develops therapies for inflammatory autoimmune diseases. Find out why I'm bearish on APGE stock.

Hangzhou Bio-Creativity Pharma-Tech Co. Ltd. has disclosed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of atopic dermatitis.

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors ... on SAR444656 may represent a significant opportunity for competition in AD treatment and may introduce a ...